How Generic Drug Makers Are Responding to Price-Fixing Lawsuit
WASHINGTON, DC (May 16, 2019) — AAM President and CEO Chester “Chip” Davis, Jr. appeared on PBS Newshour last night to respond to allegations by Connecticut Attorney General William Tong, who was also a guest. Generic medicines are 90 percent of all prescriptions filled and are available for 22 percent of total cost to the […]
The 11th Annual Edition of AAM Access & Savings Report Finds Generic Savings Totaled $293 Billion in 2018
WASHINGTON, DC (May 13, 2019) — The Association for Accessible Medicines (AAM) has released details of its 2019 Access & Savings Report, with key findings that underscore the importance of generics and biosimilars to American patients. According to the forthcoming report, the U.S. health care system has saved $2 trillion in the last decade due […]
Response to 60 Minutes May 12, 2019: AAM Statement on the Importance of Competition to Promote Accessibility and Affordability of Medicines
WASHINGTON, DC (May 12, 2019) — The Association for Accessible Medicines (AAM) and its member companies are committed to supporting policies that promote competition and help speed the availability of generic and biosimilar medicines to patients. Today’s generic drug industry is characterized by intense competition. As a result, pricing data from the last three years […]
2016 Savings and Access Report
Generic Medicines Drive Savings, Not Costs The generic pharmaceutical industry plays an important role in the health system and generic drug manufacturers are true drivers of health system value — generating savings and enhancing access for patients, public programs, taxpayers, employers and others who rely on more affordable medicines. The 8th annual 2016 Generic Drug […]
AAM Statement: 2019 Energy and Commerce Health Subcommittee Markup
WASHINGTON, DC (March 27, 2019) – The generic and biosimilar industry greatly appreciates the efforts of the Energy and Commerce Health Subcommittee to pass the CREATES Act and advance this bipartisan market-based solution to end abuse of FDA’s safety programs. Today’s markup, unfortunately, represents one step forward and two steps back for patients who want competition […]
HHS Proposal Will Help America’s Patients Realize the Full Value of Their Generics and Biosimilars
America’s patients continue to cite high prescription drug costs as a major issue, and the Trump administration has responded with a series of proposals to reduce out-of-pocket costs for patients and overall spending on high-priced brand drugs. While its recent, bold proposal to ban brand drug manufacturers from offering rebates for preferred formulary access for […]
Patient Victory: Supreme Court Denies Review of Drug Pricing Law HB 631
WASHINGTON, DC (February 19, 2019) – Today’s decision is a victory for patients who depend on a strong national market for generic and biosimilar medicines. Maryland’s law would have allowed one state to dictate prices in the competitive national market for generic medicines that saved patients and taxpayers $265 billion in 2017. The Association for […]
AAM Statement on Trump Administration’s Proposal to Lower Drug Costs by Targeting Backdoor Rebates
WASHINGTON DC (February 1, 2019) – “AAM applauds the Administration’s efforts to reduce high brand drug costs for patients. Too often, brand drug companies are using rebate traps to block patient access to more affordable generic or biosimilar medicines. We look forward to reviewing the proposal and working with the Administration to ensure that America’s […]
From Sea to Shining Sea: Generic Savings State by State
Safe, reliable generic prescription drugs enable Americans to save money at the pharmacy counter. The government saves big, too, on medicine for seniors and low-income people. In 2017, overall savings came to $265 billion. AAM’s annual generic drug savings and access report presents the independent findings of IQVIA regarding the savings that our companies bring […]
BCBS: It’s time to CREATE more choices & lower drug prices
Biologic drugs are pushing the boundaries of medicine, and their potential to benefit patients with unmet medical needs has never been more promising. For example, researchers are using a viral therapy to treat advanced melanoma by targeting only cancerous cells, and prompting the patient’s immune system to attack them as well. But all too often […]
$13.4 Billion a Year! Brand “Shenanigans” Are Costing Patients More Than Ever
When a brand-name prescription drug’s market exclusivity (its monopoly) and patents expire, generic and biosimilar medicines become available, the savings begin and patients win. That’s how the system is supposed to work. However, brand-name pharmaceutical companies have increasingly abused FDA’s safety programs (Risk Evaluation and Mitigation Strategies, or REMS) and other manufacturer-imposed restricted distribution of […]
New Study Finds Patients, Government and Insurance Lose $13.4B in Potential Savings By Brand Drug Companies’ Abuses
Study Finds Costs of Brand Abuses Have Exploded in 4 Years, Harming Patient Access to Affordable Generic and Biosimilar Medicines WASHINGTON DC (September 4, 2018) – Continued efforts to delay patient access to biosimilar and generic drugs have an increasing negative impact on patients, according to an updated report released today by Matrix Global Advisors […]
